title: Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
authors.forename: Thomas
authors.initials: T
authors.lastname: Prebet
authors.forename: Aude
authors.initials: A
authors.lastname: Charbonnier
authors.forename: Véronique
authors.initials: V
authors.lastname: Gelsi-Boyer
authors.forename: Marie Joelle
authors.initials: MJ
authors.lastname: Mozziconacci
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
mesh_terms: D001374:Azacitidine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide; D001374:Azacitidine